Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo biological standardization of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergenic extracts
2026-525628-13-00Phase 2Authorised
- Sponsor
- Probelte Pharma
- Start
- Jun 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dermatophagoides pteronyssinus and dermatophagoides farinae allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma and 1 more (2 arms), sponsored by Probelte Pharma. Primary endpoint: In vivo determination of biological activity of DPT and DF allergenic extracts. Planned start Jun 2026; status: authorised.
02
Drugs
dermatophagoides pteronyssinusdermatophagoides farinae allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2026-525628-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525628-13-00.